Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

Head & Neck ◽  
2020 ◽  
Vol 42 (4) ◽  
pp. 599-607 ◽  
Author(s):  
Assaf Moore ◽  
Yael Bar ◽  
Corinne Maurice‐Dror ◽  
Inna Ospovat ◽  
Michal Sarfaty ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Salivary Gland Carcinoma ◽  
Next Generation ◽  
Therapeutic Advantage ◽  
Gland Carcinoma ◽  
Generation Sequencing

Mutational Landscape of Primary Pulmonary Salivary Gland-type Tumors through Targeted Next-Generation Sequencing

Lung Cancer ◽  
2021 ◽  
Author(s):  
Fang Wang ◽  
Shao-Yan Xi ◽  
Wen-Wen Hao ◽  
Xin-Hua Yang ◽  
Ling Deng ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Next Generation ◽  
Mutational Landscape ◽  
Targeted Next Generation Sequencing ◽  
Generation Sequencing ◽  
Gland Type

Next‐generation sequencing assay in salivary gland cytology: A pilot study

2020 ◽  
Vol 49 (10) ◽  
pp. 1037-1043
Author(s):  
Shuhei Yamamoto ◽  
Yuma Sakamoto ◽  
Satsuki Nakano ◽  
Keiichiro Fujii ◽  
Kaori Ueda ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Pilot Study ◽  
Next Generation ◽  
Generation Sequencing

scholarly journals Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?

Medicine ◽  
2021 ◽  
Vol 100 (25) ◽  
pp. e26388
Author(s):  
Assaf Moore ◽  
Yael Bar ◽  
Corinne Maurice-Dror ◽  
Inbar Finkel ◽  
Hadar Goldvaser ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Next Generation ◽  
Thyroid Cancers ◽  
Therapeutic Advantage ◽  
Generation Sequencing

scholarly journals Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing

2020 ◽  
Vol 14 (2) ◽  
pp. 311-320 ◽  
Author(s):  
Emilija Todorovic ◽  
Brendan C. Dickson ◽  
Ilan Weinreb
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Salivary Gland Cancer ◽  
Next Generation ◽  
Generation Sequencing

scholarly journals SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets

Neoplasia ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. 473-487
Author(s):  
Sandra N. Freiberger ◽  
Muriel Brada ◽  
Christine Fritz ◽  
Sylvia Höller ◽  
Alexander Vogetseder ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Therapeutic Targets ◽  
Salivary Gland Neoplasm ◽  
Next Generation ◽  
Generation Sequencing

Next Generation Sequencing in Salivary Gland Carcinomas: Do Actionable Mutations Lead to a Therapeutic Advantage? A Multicenter Experience.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17582-e17582
Author(s):  
Assaf Moore ◽  
Orit Gutfeld ◽  
Salem Billan ◽  
Yael Bar ◽  
Corinne Maurice Dror ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Pik3ca Mutation ◽  
Genetic Alterations ◽  
Targeted Treatment ◽  
Tumor Control ◽  
Second Line ◽  
Next Generation ◽  
Salivary Gland Carcinomas ◽  
Generation Sequencing

e17582 Background: Salivary gland cancers (SGCs) are rare tumors. The approach to recurrent or metastatic patients is histology dependent, as the clinical course is highly variable. Response rates to chemotherapy are modest and no second-line therapies have proven to be effective. The rarity and heterogeneity of SGCs make conducting clinical trials challenging. Recent reports of Next Generation Sequencing (NGS) in SGCs have identified unique genetic attributes of certain histological classes. However, despite the elaborate work done with genetic characterization, there is very little evidence on whether these findings translate to tumor control. In this study, we aimed to explore the treatment outcomes of patients with advanced SGCs who underwent a commercially available NGS. Methods: A retrospective analysis of all patients with histologically confirmed SGC treated in three major Israeli cancer centers who underwent NGS. Results: Twenty-seven patients were included. Eighteen patients were male (66.6%). The median age was 59 (range 38-81). Histologic type was adenoid cystic carcinoma in 11 (40.7%) patients, 8 (29.6%) mucoepidermoid carcinomas, 5 (18.5%) adenocarcinomas, 2 (7.4%) salivary duct carcinomas and 1 (3.7%) acinic cell carcinoma. Twenty-five (92.6%) had recurrent disease after initial curative treatment and 2 were initially diagnosed with metastatic disease. Median time to recurrence was 24.3 months. The median number of systemic treatment lines was 1 (range 0-5). Thirteen patients (48%) had targetable findings in NGS, including: 5 ERBB2 amplifications, 3 PIK3CA mutation, 1 TRIM33-RET fusion, 1 FGFR3-TACC3 fusion, 1 MSI-high and 2 high mutational burden. Nine patients were treated accordingly; 5 in the second-line and 4 as first-line treatment. Median progression-free survival for targeted treatment was 8.4 months. Of 4 patients who achieved durable responses to anti-RET/HER2 agents and immunotherapy of 8.4 – 31.1 months, two are ongoing. The median overall survival for all patients was 101.75 months, was not reached for patients receiving targeted treatment and was 40.4 months for patients treated conventionally (p = 0.26). Conclusions: In the absence of a well-established therapeutic approach, NGS may detect clinically significant genetic alterations and benefit patients with advanced SGCs.

scholarly journals De novo Ixodes ricinus salivary gland transcriptome analysis using two next‐generation sequencing methodologies

2013 ◽  
Vol 27 (12) ◽  
pp. 4745-4756 ◽  
Author(s):  
Alexandra Schwarz ◽  
Björn M. Reumont ◽  
Jan Erhart ◽  
Andrezza C. Chagas ◽  
José M. C. Ribeiro ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Ixodes Ricinus ◽  
Transcriptome Analysis ◽  
De Novo ◽  
Next Generation ◽  
Generation Sequencing

scholarly journals Next-Generation Sequencing in Salivary Gland Basal Cell Adenocarcinoma and Basal Cell Adenoma

2016 ◽  
Vol 10 (4) ◽  
pp. 494-500 ◽  
Author(s):  
Thomas C. Wilson ◽  
Deqin Ma ◽  
Anup Tilak ◽  
Brennan Tesdahl ◽  
Robert A. Robinson
Keyword(s):  
Salivary Gland ◽  
Next Generation Sequencing ◽  
Basal Cell ◽  
Basal Cell Adenoma ◽  
Next Generation ◽  
Cell Adenoma ◽  
Basal Cell Adenocarcinoma ◽  
Generation Sequencing

Next-Generation Sequencing

2012 ◽  
Vol 42 (9) ◽  
pp. 8
Author(s):  
PETER HULICK
Keyword(s):  
Next Generation Sequencing ◽  
Next Generation ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document